Compare NGL & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NGL | HROW |
|---|---|---|
| Founded | 1940 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2011 | 2008 |
| Metric | NGL | HROW |
|---|---|---|
| Price | $15.43 | $30.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $65.00 |
| AVG Volume (30 Days) | 149.9K | ★ 486.5K |
| Earning Date | 11-03-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 71.43 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,156,159,000.00 | N/A |
| Revenue This Year | $5.18 | $28.81 |
| Revenue Next Year | N/A | $53.97 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.88 | $28.54 |
| 52 Week High | $19.06 | $54.98 |
| Indicator | NGL | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 30.96 | 27.10 |
| Support Level | $14.26 | $28.54 |
| Resistance Level | $16.70 | $35.43 |
| Average True Range (ATR) | 0.55 | 1.25 |
| MACD | -0.23 | -0.21 |
| Stochastic Oscillator | 10.03 | 11.48 |
NGL Energy Partners LP is a USA-based firm that owns and operates a vertically integrated energy business. The company's operating segments include Crude Oil Logistics, Water Solutions, and Liquids Logistics. It operates crude oil Logistics, owns pipeline injection stations, and offers services for the treatment and disposal of wastewater generated from crude oil and natural gas production, as well as for the disposal of solids, such as tank bottoms and drilling fluids. The firm also supplies natural gas liquids to retailers, wholesalers, refiners, and petrochemical plants and sells propane and distillates.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.